ralimetinib ralimetinib ralimetinib (ly2228820) is a small molecule experimental cancer drug in development by eli lilly. it is a p38 mitogen-activated protein kinase inhibitor. ralimetinibralimetinib structural formulaclinical dataother namesly2228820routes ofadministrationpoatc codenoneidentifiers iupac name 5--3-(2,2-dimethylpropyl)imidazopyridin-2-amine cas number862505-00-8 ypubchem cid11539025chemspider9713805unii73i34xw4hdkeggd10658 ycomptox dashboard (epa)dtxsid00235456 chemical and physical dataformulac24h29fn6molar mass420.536 g·mol−13d model (jsmol)interactive image smiles c12c(=cc=c(n=1)c1=c(n=c(n1)c(c)(c)c)c1c=cc(=cc=1)f)n=c(n2cc(c)(c)c)n inchi inchi=1s/c24h29fn6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12h,13h2,1-6h3,(h2,26,28)(h,29,30)key:xppbbjcbdoexdn-uhfffaoysa-n a phase ii trial for treatment of ovarian cancer has completed.